Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Find more clinical trials

LY3002813 for Early Alzheimer's Disease (TRAILBLAZER-ALZ)

Start: December 18, 2017
End: September 2021
Enrollment: 266

What Is This Study About?

TRAILBLAZER-ALZ aims to evaluate the safety, tolerability, and efficacy of the investigational drug LY3002813 in early symptomatic Alzheimer's disease.

Do I Qualify To Participate in This Study?

Minimum Age: 60 Years

Maximum Age: 85 Years

Must have:

  • Gradual and progressive change in memory function for 6 months or longer
  • Mini-Mental State Examination score of 20 to 28 or a flortaucipir positron emission tomography (PET) scan within past 6 months that meets criteria
  • Meet criteria for 18F flortaucipir and 18F florbetapir PET scans

Must NOT have:

  • History of long QT syndrome
  • Use of a stable dose of an acetylcholinesterase inhibitor, such as donepezil (Aricept), galantamine (Razadyne), and rivastigmine (Exelon), and/or memantine (Namenda) for less than 2 months before randomization
  • Inability to undergo magnetic resonance imaging

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

Who Is the General Study Contact?

For more information about this study or study sites, visit the TRAILBLAZER-ALZ study website, email clinicaltrials.gov@lilly.com, or call 1-877-285-4559 or 1-317-615-4559 Monday-Friday 9 a.m. to 5 p.m. Eastern.

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: Eli Lilly and Company

Source: ClinicalTrials.gov ID: NCT03367403

alzheimers.gov

An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health